Table 6.

Recurrence rates of chemotherapy versus surveillance in studies with non-seminomatous GCT patients in cSI [22, 23, 24, 32, 33]

Reference	N	Therapy	Recurrence rate, %
[22]	234	Surveillance	30.0
	148	1–2× PEB	4.0 (6.5+3.6)
[23]	231	2× PEB (hr)	0.8
	358	surveillance (lr)	19.0
[32]	60	2× CVB (hr)	1.6
	124	surveillance/	12.9
	40	1× CVB (lr)	10.0
[33]	258	1× PEB (hr)	3.1
	255	1× PEB/surveillance (lr)	1.6
[24]	167	2× PEB (hr)	1.2
	287	surveillance (lr)	16.7

GCT, germ cell tumour; cSI, clinical stage I; hr, high risk; lr, low risk.